FindTrial
Sign In

The clinical study of the treatment of hilar lung carcinoma with Cyberknife

The clinical study of the treatment of hilar lung carcinoma with Cyberknife

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17013903
Enrollment
Unknown
Registered
2017-12-13
Start date
2017-12-01
Completion date
Unknown
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Case series:Cyberknife

Sponsors

Peking University Third Hospital, Department of Radiation Oncology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with primary or metastatic tumors of the eyes 2. T3-4N0M0 NSCLC; T3-4N0M1 (Oligo-metastases); T3-4NX M0-1(Local palliative treatment of symptoms caused by hilar lesions).

Exclusion criteria

Exclusion criteria: 1. Local lesions are not suitable for SRS; 2. Body poor constitution could not accept SRS

Design outcomes

Primary

MeasureTime frame
local contronl;—

Secondary

MeasureTime frame
PFS,OS;—

Countries

China

Contacts

Public ContactHongqing Zhuang

Peking University Third Hospital, Department of Radiation Oncology

yiduzhengmu@163.com+86 13051776232

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026